- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02288000
Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases (WP3_P002)
Effect of a 15-day Memantine Treatment on Biomarkers of AD in Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim of the present study is to test the effect of a 15-day treatment with memantine on a mixed battery associating cognitive assessment, imaging and neurophysiological tests in healthy volunteers.
This multicenter, randomized, placebo-controlled, cross-over study is double-blind controlled and is conducted in 3 centers located in France (Lille, Marseille and Toulouse).
18-30 years old, healthy volunteers, without any neurological or psychiatric impairment, will complete 2 test sessions in a randomized order: one with a 15-day treatment with memantine, the other with placebo, and will be submitted to a mixed battery during the 14th and 15th day of the treatment. The primary outcome of the study will be based on cognitive assessment, imaging parameters and neurophysiological parameters
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Régis Bordet, MD, PhD
- Phone Number: +33 +33 (0)3 20 44 54 49
- Email: regis.bordet@univ-lille2.fr
Study Locations
-
-
-
Lille, France, 59037
- Recruiting
- CHRU de Lille/ Centre d'investigation Clinique
-
Contact:
- Dominique Deplanque, PH
- Email: dominique.deplanque@chru-lille.fr
-
Marseille, France
- Not yet recruiting
- CIC Marseille
-
Contact:
- OLIVIER BLIN
- Email: olivier.blin@ap-hm.fr
-
Toulouse, France
- Not yet recruiting
- CIC Toulouse
-
Contact:
- Olivier Rascol
- Email: cic9302@purpan.inserm.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-30 year old male non-smoker subjects
- Subject without cognitive impairment or cognitive complaint (Moca>26, Mac Nair scale<15)
- Subject without history of brain disease (severe brain trauma, stroke, cerebral tumor,…)
- Subject without major medical or surgical history
- Subject without current chronic disease
- Subject without current cerebral disease
- Subject without vascular or metabolic risk factor
- Subject without history or current mental disease or addiction (MINI)
- Subject without lesion on MRI
- Subject without abnormal electrical activities on EEG
- Subject without use of chronic treatment or psychotropic drugs or substances
- French speaker subject and able to understand the test instructions
Exclusion Criteria:
- Subject with dementia or cognitive decline identified by Moca < 26
- Subject with vascular or metabolic risk factor
- Subject with history or current mental disease or addiction
- Subject with family history of young-onset dementia
- Subject with family history of chronic or severe neurological or mental disease (first degree relatives)
- Subject receiving a chronic treatment
- Subject with claustrophobia or contra-indication to MRI
- Subject unable to understand the test instructions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Memantine
Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
|
Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
Other Names:
|
Placebo Comparator: Placebo
The placebo will be presented as capsule comparable to memantine
|
the placebo will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacog battery
Time Frame: 15 days
|
|
15 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Régis Bordet, MD, PhD, University Hospital, Lille
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Alzheimer Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Dopamine Agents
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Memantine
Other Study ID Numbers
- 2012_55
- 2013-001671-21 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Memantine
-
Lyndra Inc.TerminatedHealthy | Gastric RetentionUnited Kingdom
-
Chong Kun Dang PharmaceuticalCompletedAlzheimer's Disease (AD)Korea, Republic of
-
HaEmek Medical Center, IsraelUnknown
-
Merz Pharmaceuticals GmbHLLC Merz Pharma, RussiaCompleted
-
Tianjin Medical University Second HospitalRecruiting
-
GeropharmCompletedBioequivalence, AUC, Cmax, PharmacokineticsRussian Federation
-
H. Lundbeck A/SCompletedAlzheimer Dementia (AD)China
-
University of UtahActive, not recruiting
-
University of Kansas Medical CenterUniversity of Missouri-ColumbiaCompletedAmyotrophic Lateral Sclerosis | Frontal Temporal DementiaUnited States
-
Kenneth Myers, MDCompleted